Moderna Inc (MRNA) Stock Analysis
Verdict: AVOID
Surging cash burn of -$2.07B FCF and steep 26.4x P/S multiple make MRNA vulnerable to a sharp rerating without oncology commercialization.
Investment score: 31/100
Analysis as of
Is Moderna Inc stock worth reviewing? AI model thesis
Moderna trades at a stretched 26.38x P/S multiple with negative operating margins (-149.01%) and -$2.07B annual FCF burn, leaving the current price 28% above analyst consensus.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Moderna Inc opportunities and risks
What speaks for MRNA
- Pipeline Diversification into Oncology and CMV
What speaks against MRNA
- High FCF Burn Rate and Short Cash Runway
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MRNA | n/a | 26.4x | n/a | -12.6% | -141.4% | -2.1% |
| AMGN | 23.4x | 5.4x | 15.0x | 72.7% | 22.9% | 5.0% |
| GILD | n/a | 5.9x | 317.4x | 79.6% | -10.6% | 7.4% |
| VRTX | 29.8x | 10.4x | 23.3x | 86.0% | 34.9% | 2.9% |
| REGN | 18.7x | 5.2x | 13.9x | 84.9% | 27.9% | 4.4% |
| Peer median | 21.0x | 5.6x | 19.2x | 82.2% | 25.4% | 4.7% |
Frequently asked questions about Moderna Inc (MRNA)
Is MRNA stock a good investment?
The cached TradeMates AI model rates Moderna Inc as AVOID with an investment score of 31/100. Moderna trades at a stretched 26.38x P/S multiple with negative operating margins (-149.01%) and -$2.07B annual FCF burn, leaving the current price 28% above analyst consensus. This is algorithmic model output, not personal investment advice.
Is MRNA stock a buy?
The TradeMates model verdict for MRNA is AVOID with an investment score of 31/100. Treat this as a model signal to review, not a personal buy recommendation.